人民财讯12月26日电，12月26日，上海证券交易所发布《上海证券交易所发行上市审核规则适用指引第 9号——商业火箭企业适用科创板第五套上市标准》，明确适用科创板第五套上市标准的商业火箭企业 主营业务为"商业火箭自主研发、制造及航天发射服务"，更加看重发行人的"硬科技"属性。要求企业需 在拥有关键核心技术基础上具备明显技术优势或重大突破，关注核心技术产品以及关键部件的自主研发 情况，以及运载能力及一箭多星能力等关键指标。对于承担国家任务、参与国家工程项目的商业火箭企 业予以优先支持。 ...

超10家商业航天独角兽集体奔赴IPO 据21世纪经济报道记者不完全统计，目前已有十余家商业行业企业启动了IPO进程。除了蓝箭航天外， 星河动力、中科宇航、微纳星空、屹信航天、天兵科技、爱思达航天、星际荣耀均已在当地证监局进行 辅导，拟冲刺A股上市；另外国星宇航、福信富通则将目标瞄准了港股。 各大券商显然也不想错过这轮IPO新机遇，竞相参与到商业航空"独角兽"上市项目的争夺中。 近日，证监会网站显示，蓝箭航天IPO辅导状态已变更为"辅导工作完成"，距离正式递表仅一步之遥。 当前，商业航天市场热度持续高涨。目前国内商业航天企业数量已超600家，覆盖卫星制造、火箭发 射、地面设备、终端应用全产业链。 今年6月，科创板"1+6"改革规则落地，重启未盈利企业适用科创板第五套标准上市并扩大适用范围，明 确支持人工智能、商业航天、低空经济等更多前沿科技领域企业上市，商业航天企业开始扎堆筹备 IPO。 "其实前两年，市场就已经出现了将科创板第五套上市标准扩围至商业航天领域的呼声，有很多同行从 那个时候就开始注意这个领域的项目。科创板新政的出台，就是一个'起跑信号'，前期有项目储备的走 得很快。"华南一名资深的保代受访表示。 ...

转自：北京日报客户端 共8家医药企业排队 截至12月25日，科创板IPO排队的医药企业共有8家，均为以科创板第五套标准申报上市。其中北芯生 命距离上市最近，已注册生效。 上交所官网于12月22日更新了北芯生命的IPO动态，公司科创板IPO已于12月18日注册生效。招股书显 示，北芯生命是一家专注于心血管疾病精准诊疗创新医疗器械研发、生产和销售的国家高新技术企业。 从北芯生命IPO历程可以看出近年来科创板IPO对未盈利医药企业监管态度的变化。回顾北芯生命科创 板IPO历程，公司IPO于2023年3月30日获得受理，随后于当年4月进入问询阶段。随着科创板重启第五 套上市标准审核，北芯生命于今年7月18日上会获得通过，并于7月25日提交注册，目前已注册生效。 作为一家以科创板第五套上市标准申报上市的企业，北芯生命申报IPO之初报告期内净利均为亏损。不 过在IPO排队过程中，北芯生命实现了扭亏。根据公司注册稿，今年一季度，北芯生命实现的营业收入 为1.28亿元，同比增长104.9%；对应实现的归属净利润为2060.61万元，同比实现扭亏。 此外，随着科创板第五套上市标准重启，今年以来，有5家未盈利医药企业科创板IPO ...

随着商业化持续推进，深圳北芯生命科技股份有限公司（以下简称"北芯生命"）已实现扭亏，同时这家 近期注册生效的医疗器械企业也即将进入发行阶段，成为科创板第五套上市标准下医药企业冲刺资本市 场的生动样本。今年以来，随着科创板第五套上市标准审核重启，沉寂一段时间的医药企业科创板IPO 市场迎来新生机。 经统计，年内已有珠海泰诺麦博制药股份有限公司（以下简称"泰诺麦博"）等6家医药企业科创板IPO获 得受理。截至目前，科创板IPO排队医药企业共8家，均为以科创板第五套标准申报上市。值得一提的 是，上海恒润达生生物科技股份有限公司（以下简称"恒润达生"）、哈尔滨思哲睿智能医疗设备股份有 限公司（以下简称"思哲睿"）早在2022年便开始闯关，不过自科创板IPO第五套上市标准重启后，除更 新财务资料外尚未有新进展。 8家药企排队 截至12月25日，科创板IPO排队的医药企业共有8家，均以科创板第五套标准申报上市。其中，北芯生 命距离上市最近，已注册生效。12月22日，上交所官网更新了北芯生命的IPO动态，公司科创板IPO已 于12月18日注册生效。招股书显示，北芯生命为一家专注于心血管疾病精准诊疗创新医疗器械研发、生 产和 ...

| 卫星互联网 | | | 大飞机 +4.70% | | 卫星导航 +3.90% | +3.85% | | --- | --- | --- | --- | --- | --- | --- | | 十大军工集 人形机器人 | | | | 通用航空 +3.27% | +3.22% | +3.17% | | | 商业航天 +4.95% 低空经济 +3.76% 航母 +3.59% | | | | | | | | | 军工信息化 +3.38% 中航系 | | | | | | T 4.0 | | | 宇树机器人 | | 汽车配件精 | | | +2.65% | | +3.15% | | +3.03% | +2.78% | | | G | 商业航天指数(8841877) | | | | --- | --- | --- | --- | | | 19392.20 914.87 4.95% | | | | 资料 | 成分 资讯 相关基金 | | 月度收益 | | 名称 | | 现价 | 涨跌幅 == | | 超捷股份 | | 134.93 | 20.00% | | 301005.SZ | | | | | 广联航空 | | 31. ...

商业航天领域IPO再传来重磅进展。 近日，证监会网站显示，蓝箭航天IPO辅导状态已变更为"辅导工作完成"，距离正式递表仅一步之遥。 当前，商业航天市场热度持续高涨。目前国内商业航天企业数量已超600家，覆盖卫星制造、火箭发 射、地面设备、终端应用全产业链。 今年 6 月，科创板"1+6"改革规则落地，重启未盈利企业适用科创板第五套标准上市并扩大适用范围， 明确支持人工智能、商业航天、低空经济等更多前沿科技领域企业上市，商业航天企业开始扎堆筹备 IPO。 据21世纪经济报道记者不完全统计，目前已有十余家商业行业企业启动了IPO进程。除了蓝箭航天外， 星河动力、中科宇航、微纳星空、屹信航天、天兵科技、爱思达航天、星际荣耀均已在当地证监局进行 辅导，拟冲刺 A 股上市；另外国星宇航、福信富通则将目标瞄准了港股。 各大券商显然也不想错过这轮IPO新机遇，竞相参与到商业航空"独角兽"上市项目的争夺中。 "其实前两年，市场就已经出现了将科创板第五套上市标准扩围至商业航天领域的呼声，有很多同行从 那个时候就开始注意这个领域的项目。科创板新政的出台，就是一个'起跑信号'，前期有项目储备的走 得很快。"华南一名资深的保代受访表 ...

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. (Tainuo Maibo) has become a market focus as the first company to apply for listing under the fifth set of standards for the Science and Technology Innovation Board (STAR Market) after its restart. The company disclosed its first round of inquiry responses, revealing that the actual sales of its core product, Staidotat Monoclonal Antibody, fell short of expectations, achieving only 47.6% of the projected sales volume [1][4][5]. Sales Performance - As of September 30, the actual sales of Staidotat Monoclonal Antibody were 4.61 million bottles, compared to an expected 9.69 million bottles, resulting in a completion ratio of 47.6% [5][6]. - The self-operated team had an expected sales volume of 5.68 million bottles but achieved only 4.35 million bottles (completion ratio of 76.67%), while the external promotion service team expected 4.01 million bottles but only sold 0.26 million bottles (completion ratio of 6.42%) [5][6]. Financial Overview - Tainuo Maibo's sales expenses are significant, with projected sales expenses of 3.89 million, 12.42 million, and 35.11 million for the years 2022 to 2024, respectively. In the first quarter of this year, sales expenses reached 24 million [7][8]. - The company reported a net loss of approximately 4.29 billion, 4.46 billion, and 5.15 billion for the years 2022 to 2024, with a net loss of about 1.77 billion in the first quarter of this year [8]. Debt and Financial Health - The asset-liability ratio of Tainuo Maibo has significantly increased, with ratios of 16.54%, 28.19%, 58.96%, and 56.5% for the years 2022 to 2025 Q1. This ratio is higher than the average of comparable companies [10][11]. - The increase in the asset-liability ratio is attributed to increased spending on drug research and commercialization team building, alongside a decrease in cash reserves [12]. IPO and Fundraising - Tainuo Maibo aims to raise 1.5 billion for new drug research projects, expansion of antibody production bases, and to supplement working capital, with allocations of 830 million, 330 million, and 340 million, respectively [9].

Core Points - Shenzhen Core Medical Technology Co., Ltd. has become the first innovative medical device company to submit an IPO application under the reactivated fifth set of listing standards for the Sci-Tech Innovation Board [1][5] - The company focuses on providing comprehensive, innovative, and high-quality artificial heart products, addressing significant clinical needs in acute and chronic heart failure [3][4] - Core Medical has developed 5 implantable and 6 interventional artificial heart products, with one implantable product already commercialized and two interventional products in the registration approval stage [3][4] Financial Performance - Core Medical has not yet achieved profitability, with projected revenues of approximately 0, 16.55 million, 93.69 million, and 70.48 million CNY for the years 2022 to 2025, and net losses of approximately -178 million, -170 million, -132 million, and -72.75 million CNY for the same periods [4] - As of June 30, the company reported cumulative undistributed profits of -367 million CNY, indicating ongoing financial challenges [4] Market Position and Challenges - The artificial heart industry in China is still in its early development stages, with commercialization affected by factors such as clinical penetration, discipline development, surgical promotion, and patient payment capabilities [4] - Core Medical aims to become the first company to obtain approval for interventional artificial heart products in China, facing challenges in product promotion, market education, and brand building [4][5] IPO Details - The company plans to raise up to 1.217 billion CNY through its IPO, with funds allocated for research and development of circulatory support products, establishment of an artificial heart industrialization base, marketing network and digital construction, and working capital [5] - Core Medical meets the listing standards set forth in the Sci-Tech Innovation Board's regulations, which emphasize technological advancement and research capabilities over short-term financial metrics [5]

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. has had its IPO application accepted by the Shanghai Stock Exchange, marking it as the first innovative medical device company to be accepted under the newly reinstated fifth set of listing standards for the Sci-Tech Innovation Board [1] Group 1 - Core Medical has received investments from multiple seasoned professional institutional investors [1] - It is the second company to be recognized as having seasoned professional institutional investors after Zhuhai Tenomab Pharmaceutical Co., Ltd. [1]

Core Points - Shenzhen Core Medical Technology Co., Ltd. has had its IPO application accepted by the Shanghai Stock Exchange on November 6, marking it as the first innovative medical device company to be accepted under the fifth set of listing standards for the Sci-Tech Innovation Board [1] - The prospectus indicates that Core Medical has received investments from multiple qualified institutional investors, making it the second company after Zhuhai Tenomab Pharmaceutical Co., Ltd. to be recognized as having qualified institutional investors in its Sci-Tech Innovation Board application [1]